The American Journal of Managed Care

Current Treatment Options For Bronchiectasis

Dr Metersky provides an overview of current treatment strategies for managing patients diagnosed with bronchiectasis. The main bronchiectasis management goals are improving quality of life, decreasing ...
The American Journal of Managed Care

First-in-Class Brensocatib Could Help Treat Patients With Bronchiectasis: James Chalmers, MD

The approval of brensocatib for use in patients with bronchiectasis could offer the first treatment directly addressing the roots of the condition. What is bronchiectasis and how can the condition be ...
Seeking Alpha

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a ...
Healio

FDA grants brensocatib priority review for bronchiectasis

Please provide your email address to receive an email when new articles are posted on . Brensocatib given as 25 mg performed better than placebo when assessing rate of pulmonary exacerbations and lung ...
Morningstar

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...
PR Newswire

European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

— BRINSUPRI Was Reviewed Under EMA's Accelerated Assessment Pathway as It Is Considered of Major Interest for Public Health — BRIDGEWATER, N.J., Nov. 18, 2025 /PRNewswire/ -- Insmed Incorporated ...